Breaking News Instant updates and real-time market news.

TTD

Trade Desk

$93.31

1.98 (2.17%)

, PBYI

Puma Biotechnology

$48.75

0.4 (0.83%)

19:08
08/09/18
08/09
19:08
08/09/18
19:08

On The Fly: After Hours Movers

UP AFTER EARNINGS: Trade Desk (TTD) up 19.8%... Puma Biotech (PBYI) up 17.2%... Universal Display (OLED) up 9.1%... ICUI Medical (ICUI) up 7.6%... Construction Partners (ROAD) up 5.6%... Spectrum Pharma (SPPI) up 5.4%... Altair (ALTR) up 3.5%... WideOpenWest (WOW) up 3.4%... Lions Gate Entertainment (LGF) up 3.2%... Planet Fitness (PLNT) up 2.5%... Air Lease (AL) up 2.0%... Synaptics (SYNA) up 1.5%. ALSO HIGHER: Overstock (OSTK) up 15.3% after disclosing GSR Capital is investing in blockchain subsidiary tZERO... Tesla (TSLA) up 2.0% after CNBC report that the Board will discuss going-private transaction next week. DOWN AFTER EARNINGS: Corcept Therapeutics (CORT) down 21.3%... Sunrun (RUN) down 11.1%... Avalara (AVLR) down 10.8%... Redfin (RDFN) down 9.6%... Dropbox (DBX) down 8.4%... Microchip (MCHP) down 7.3%... J2 Global (JCOM) down 5.1%... Chuy Holdings (CHUY) down 4.7%... Mimecast (MIME) down 4.2%... Endologix (ELGX) down 4.0%... Acxiom (ACXM) down 2.0%... Funko (FNKO) down 1.6%.

TTD

Trade Desk

$93.31

1.98 (2.17%)

PBYI

Puma Biotechnology

$48.75

0.4 (0.83%)

OLED

Universal Display

$101.10

-0.9 (-0.88%)

ICUI

ICU Medical

$296.30

10.55 (3.69%)

ROAD

Construction Partners

$11.26

0.25 (2.27%)

SPPI

Spectrum

$20.21

-0.79 (-3.76%)

ALTR

Altair

$36.49

1.21 (3.43%)

WOW

WideOpenWest

$10.93

0.1 (0.92%)

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

PLNT

Planet Fitness

$48.88

0.55 (1.14%)

AL

Air Lease

$44.15

-0.21 (-0.47%)

SYNA

Synaptics

$48.15

-0.995 (-2.02%)

OSTK

Overstock.com

$38.60

1.55 (4.18%)

TSLA

Tesla

$352.08

-18.12 (-4.89%)

CORT

Corcept Therapeutics

$14.00

-0.08 (-0.57%)

RUN

Sunrun

$14.33

0.03 (0.21%)

AVLR

Avalara

$46.05

3.55 (8.35%)

RDFN

Redfin

$23.12

0.44 (1.94%)

DBX

Dropbox

$34.40

2.86 (9.07%)

MCHP

Microchip

$98.07

0.3 (0.31%)

JCOM

j2 Global

$86.34

0.735 (0.86%)

CHUY

Chuy's

$30.90

0.25 (0.82%)

MIME

Mimecast

$40.23

1.84 (4.79%)

ELGX

Endologix

$4.72

0.02 (0.43%)

ACXM

Acxiom

$43.33

0.52 (1.21%)

FNKO

Funko

$20.14

0.94 (4.90%)

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 09

    Aug

  • 10

    Aug

  • 10

    Aug

  • 13

    Aug

  • 14

    Aug

  • 16

    Aug

  • 04

    Sep

  • 04

    Sep

  • 10

    Sep

  • 12

    Sep

  • 12

    Sep

  • 29

    Oct

  • 06

    Nov

TTD Trade Desk
$93.31

1.98 (2.17%)

07/10/18
NOMU
07/10/18
INITIATION
NOMU
Nomura Instinet initiates coverage on Americas Internet
Nomura Instinet initiated coverage on nine names within the Americas Internet sector. The firm believes, overall, that there is "still some room for growth in digital advertising for the foreseeable future" and believes it will be led primarily by digital video and social, and primarily on mobile devices. The firm added that, as a result of slowing user growth and already high internet penetration, the growth will likely be led by pricing, rather than volume, and the consistent shift away from offline to online media. Nomura Instinet forecast the global digital advertising market "will grow at a 15% five-year CAGR through 2020 as digital ads work toward constituting half of total advertising spend," which the firm expects to occur in 2020. Nomura Instinet initiated Alphabet Class A (GOOGL), Facebook (FB), and Spotify (SPOT) with Buy ratings, and added that Alphabet and Facebook were the best positioned in this newly regulated industry. It initiated Netflix (NFLX), Snap (SNAP), Trade Desk (TTD), Criteo (CRTO), and Pandora (P) with Neutral ratings. It initiated Twitter (TWTR) with a Reduce rating, saying that while it is a "stable long-term asset that has something for everyone," the firm believes the market is pricing in "a significant advertising reacceleration that implies a shift in ad spend," while the firm expects "stability instead of a reacceleration of growth."
07/09/18
PIVT
07/09/18
INITIATION
Target $58
PIVT
Sell
Trade Desk initiated with a Sell at Pivotal Research
Pivotal Research analyst Brian Wieser initiated Trade Desk (TTD) with a Sell rating and $58 price target, stating that he believes the company can grow rapidly this year but should then see its growth decelerate. He believes its growth will plateau at a size smaller than Criteo's (CRTO), on which Wieser also initiated coverage this morning with a Buy rating.
07/09/18
07/09/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GAMESTOP STARTED WITH A BUY: Jefferies analyst Stephanie Wissink started GameStop (GME) with a Buy rating and $18 price target. Her contrarian view on the stock is that under potential new leadership with a well defined vision and execution plan, the stock's valuation, which she feels is "overlooked and overly discounted," could improve. GameStop is higher by 2.5% in midday trading. PIPER SEES CISCO LOSING SECURITY SHARE TO PALO ALTO: Piper Jaffray analyst James Fish says his firm's recent channel survey work across networking and security were weaker than he's seen in past calendar quarters for Cisco Systems (CSCO). Cisco's Security survey results were "especially weak," implying Palo Alto Networks (PANW) is taking market share, the analyst said, although the former remains his top networking pick. He kept an Overweight rating on Cisco shares, which were down almost 1% in midday trading. JEFFERIES DOWNGRADES P&G: Jefferies analyst Kevin Grundy downgraded Procter & Gamble (PG) to Hold from Buy and lowered his price target for the shares to $79 from $83. Slowing market growth, volatility in emerging markets, U.S. retail difficulties, the stronger U.S. dollar and "pricing challenges" should drive estimates lower, Grundy told investors in a research note titled "Tide Unlikely to Turn: Downgrade to Hold as Bull Thesis Wanes." Grundy said he preferred shares of Church & Dwight (CHD) and Energizer (ENR) for exposure to the Home and Personal Care space. TRADE DESK STARTED WITH A SELL: Pivotal Research analyst Brian Wieser initiated Trade Desk (TTD) with a Sell rating and $58 price target, stating that he believes the company can grow rapidly this year but should then see its growth decelerate. He believes its growth will plateau at a size smaller than Criteo's (CRTO), on which Wieser also initiated coverage this morning with a Buy rating. WELLS FARGO DOWNGRADES TWO THEME PARKS: Wells Fargo analyst Timothy Conder downgraded both SeaWorld (SEAS) and Six Flags (SIX) to Market Perform from Outperform, citing valuation, negative seasonal trading patterns, and weather impact, despite ongoing favorable consumer fundamentals and the key Q3 just starting. SeaWorld is trading down 1.3%, while Six Flags is down 1.7% at midday.
07/10/18
NOMU
07/10/18
INITIATION
Target $87
NOMU
Neutral
Trade Desk initiated with a Neutral at Nomura Instinet
Nomura initiated Trade Desk with a Neutral and $87 price target.
PBYI Puma Biotechnology
$48.75

0.4 (0.83%)

05/04/18
SBSH
05/04/18
NO CHANGE
SBSH
Buy
Puma's Nerlynx can achieve blockbuster status, says Citi
An analysis of 90 oncology drug launches indicates that products with U.S. sales of at least $200M in the first full calendar year have a greater than 50% probability of reaching $1B-plus sales, Citi analyst Yigal Nochomovitz tells investors in a research note. He believes the analysis supports his view that $1.1B of U.S. sales for Nerlynx by 2024 is an achievable goal, based on Puma Biotechnology's 2018 guidance of $175M-$200M. The analyst keeps a Buy rating on the shares.
05/10/18
SBSH
05/10/18
NO CHANGE
SBSH
Puma Biotechnology weakness a buying opportunity, says Citi
05/10/18
SBSH
05/10/18
NO CHANGE
Target $146
SBSH
Buy
Citi says Puma Biotechnology post-earnings selloff 'far overdone'
Citi analyst Yigal Nochomovitz sees several possible explanations for the post-earnings pullback in shares of Puma Biotechnology, including lower apparent demand for Nerlynx in April, the Q1 cumulative discontinuation rate having risen sequentially to 12% from 9% in the prior quarter and the fact that its third-line metastatic trial is being pushed into the second half or perhaps 2019. However, concluding that the Nerlynx launch may be stalling "seems premature," the discontinuation rate data are still "well within" his expectations and the pushback of NALA data should "only be viewed favorably" given that this is perceived by many to be a risky trial, Nochomovitz tells investors. The analyst, who recommends buying on the dip, has a Buy rating and $146 price target on Puma shares.
06/26/18
JPMS
06/26/18
NO CHANGE
Target $80
JPMS
Overweight
Positive CHMP vote a 'clear upside surprise' for Puma, says JPMorgan
JPMorgan analyst Cory Kasimov called the positive CHMP trend vote recommending approval for neratinib a "clear upside surprise" and "much needed piece of very good news" for Puma Biotechnology. Kasimov notes he had fully removed EU sales following the previous initial negative vote in January so a formal positive opinion next month and sales in early 2019 would represent "pure upside" to his estimates. The news should also likely add to neratinib's strategic value, said Kasimov, who keeps an Overweight rating and $80 price target on Puma shares.
OLED Universal Display
$101.10

-0.9 (-0.88%)

04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/18
GSCO
05/29/18
NO CHANGE
Target $150
GSCO
Buy
Goldman still constructive on Universal Display shares after conferences
Following last week's SID DisplayWeek and his firm's Technet conference in Hong Kong, Goldman Sachs analyst Brian Lee remains constructive on shares of Universal Display (OLED). The stock is rallying today after Korea's ETNews reported that Apple (AAPL) is planning to use OLED screens in all three of its iPhone models in 2019. Lee, who did not cite Apple in his research note this morning, continues to see an attractive setup into the second half of 2018 for Universal Display. Investor sentiment is "tepid" despite the potential for normalizing materials volume trends at Samsung (SSNLF) starting in Q3, continued strength in TVs, and mid-to-long term upside in blue phosphorescent, Lee wrote in a research note. The analyst reiterated a Buy rating on the shares with a $150 price target.
05/29/18
JPMS
05/29/18
NO CHANGE
JPMS
Apple OLED screen report looks like a 'false alarm,' says JPMorgan
After multiple OLED supply chain stocks reacted positively to media reports indicating that Apple (AAPL) will convert all of its new iPhone models in 2019 to OLED screens, JPMorgan analyst Jay Kwon said his findings make this appear to be a "false alarm." While he maintains his base-case view of "two OLED and one LCD" iPhones in 2019, Kwon said he also believes additional capacity build-up would be unnecessary even in an "all iPhone with OLED" scenario, as he believes current industry supply could handle an additional demand of about 50M units. The Fly notes that shares of Universal Display (OLED) are up 8% to $107.75 in morning trading following the ET News report about Apple that was quoted earlier by Apple Insider.
05/21/18
ROTH
05/21/18
INITIATION
Target $136
ROTH
Buy
Universal Display initiated with a Buy at Roth Capital
Roth Capital analyst Scott Searle started Universal Display with a Buy rating and $136 price target, citing his view that Organic Light Emitting Diodes are "an eventuality for mobile displays and ultimately TVs." Universal Display is the leading supplier of emitters and intellectual property for the OLED market, added Searle.
ICUI ICU Medical
$296.30

10.55 (3.69%)

10/17/17
KEYB
10/17/17
INITIATION
KEYB
Sector Weight
ICU Medical initiated with a Sector Weight at KeyBanc
KeyBanc analyst Matthew Mishan started ICU Medical with a Sector Weight rating saying the Hospira Infusion Systems acquisition needs time to play out.
12/14/17
RAJA
12/14/17
NO CHANGE
RAJA
Raymond James Analysts' Best Picks for 2018
Raymond James named its Analysts' Best Picks for 2018. They are: Alaska Air (ALK), Alibaba (BABA), Becton Dickinson (BDX), Broadcom (AVGO), Continental Resources (CLR), Dollar Tree (DLTR), Fastenal (FAST), First Horizon (FHN), Flir Systems (FLIR), ICU Medical (ICUI), Progressive (PGR),ProPetro Holding (PUMP), ServiceNow (NOW), SS&C (SSNC), SVB Financial (SIVB), UnitedHealth (UNH), and Weyerhaeuser (WY).
ROAD Construction Partners
$11.26

0.25 (2.27%)

05/29/18
05/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Unity Biotechnology (UBX) initiated with a Buy at Citi, an Overweight at Morgan Stanley, and a Neutral at Goldman Sachs. 2. Construction Partners (ROAD) initiated with an Outperform at Baird, a Strong Buy at Raymond James, an Overweight at Stephens, and a Buy at DA Davidson. 3. Carbon Black (CBLK) initiated with an Outperform at Cowen and William Blair, an Overweight at KeyBanc and JPMorgan, as well as an Equal Weight at Morgan Stanley. 4. Axon (AAXN) initiated with an Outperform at William Blair. 5. Spotify (SPOT) initiated with a Buy at Pivotal Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
06/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Construction Partners (ROAD) initiated with an Outperform at Imperial Capital. 2. Inovio (INO) assumed with an Overweight at Piper Jaffray. 3. GATX (GATX) initiated with a Buy at Mizuho. 4. Schneider National (SNDR) initiated with a Hold at Stifel. 5. Eloxx Pharmaceuticals (ELOX) initiated with a Buy at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
IMPC
06/29/18
INITIATION
Target $16
IMPC
Outperform
Construction Partners initiated with an Outperform at Imperial Capital
Imperial Capital analyst Adam Hackel started Construction Partners with an Outperform rating and $16 price target. The analyst sees the company positioned for long-term revenue and earnings growth due to its competitive advantages, including its vertically integrated operations and "strong" position in hot mix asphalt production. Further, Construction Partners has "robust" growth potential both organically and through its aggressive acquisition strategy, Hackel contends.
05/29/18
DADA
05/29/18
INITIATION
Target $14.5
DADA
Buy
Construction Partners initiated with a Buy at DA Davidson
DA Davidson analyst Brent Thielman initiated Construction Partners with a Buy rating and a price target of $14.50. The analyst says his view of the company's potential earnings upside is justified by faster than anticipated organic growth or M&A, supporting continued gains for the stock price. Thielman further points to an active public sector construction activity, with acceleration seen in North Carolina and a re-ramp in Georgia in addition to "relatively healthy" levels of work released in Alabama and Florida.
SPPI Spectrum
$20.21

-0.79 (-3.76%)

02/05/18
HCWC
02/05/18
NO CHANGE
Target $33
HCWC
Buy
Spectrum price target raised to $33 from $29 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Spectrum Pharmaceuticals to $33 after the company's This Advance Phase 3 study met the primary efficacy endpoint of non-inferiority in duration of severe neutropenia between Rolontis and Neulasta. The analyst is encouraged by the positive top-line data and looks forward to the full data set. He continues to believe Rolontis has blockbuster potential and projects revenue of $650M in 2024. White keeps a Buy rating Spectrum.
06/27/18
RILY
06/27/18
NO CHANGE
Target $26
RILY
Buy
Spectrum takeover report 'plausible,' says B. Riley FBR
Following a report from Bloomberg yesterday that Spectrum Pharmaceuticals is exploring options including a sale of the business amid takeover interest from other drugmakers, B. RIley FBR analyst David Buck told investors in a research note that while he has no confirmation of any takeover interest or sale process, he sees the report as "plausible." Buck, who reiterated a Buy rating, says that he continues to see his $26 per share target based on DCF and 2022E earnings power as "reasonable." Aide from any actual news on a potential transaction or sales process that gets confirmed, he expects further news flow on pipeline drug Rolontis, including a June 29 Spectrum-sponsored conference call and an expected presentation of additional poziotinib data at the World Lung Conference.
04/10/18
RILY
04/10/18
NO CHANGE
Target $26
RILY
Buy
B. Riley FBR says Spectrum likely has one more meeting before poziotinib filing
After Spectrum reported that MD Anderson's Phase 2 study of poziotinib in patients with advanced nonsmall cell lung cancer with EGFR exon 20 mutations has fully enrolled its initial 30- patient cohort and updated on the initial 11 patients, B. Riley FBR analyst David Buck said he expects one more FDA meeting before a likely filing in 2018. He reiterates a Buy rating and $26 price target on Spectrum shares.
03/13/18
HCWC
03/13/18
NO CHANGE
Target $33
HCWC
Buy
Spectrum recent weakness a buying opportunity, says H.C. Wainwright
H.C. Wainwright analyst Edward White views the recent pullback in shares of Spectrum Pharmaceuticals as a buying opportunity. The next big clinical update for poziotinib is expected in the second half of 2018, most likely at the World Conference on Lung Cancer, White tells investors in a research note. He believes the recent stock price weakness is due to some investors believing that something is wrong with the study since data will not be at ASCO. The analyst, however, reiterates that he never expected to see data at ASCO. He continues to believe the MD Anderson study is proceeding as expected and keeps a Buy rating on Spectrum with a $33 price target.
ALTR Altair
$36.49

1.21 (3.43%)

05/15/18
ADAM
05/15/18
NO CHANGE
Target $32
ADAM
Hold
Altair growing into valuation, says Canaccord
Canaccord analyst Richard Davis said Altair's Q1 results were pretty solid across the board. He said it is good to see the company growing into its valuation, which had been stretched by overzealous investors. The analyst said the current valuation is driven by the company's growth runway and investor confidence in that growth. Looking out to 2019 and 2020, the company's dynamics and valuation get more compelling, added Davis, who maintained his Hold rating and raised his price target to $32 from $30 on Altair shares.
05/15/18
BREN
05/15/18
NO CHANGE
Target $36
BREN
Buy
Altair's updated guidance remains conservative, says Berenberg
Berenberg analyst Gal Munda raised his price target for Altair Engineering to $36 from $35 after the company reported Q1 results ahead of estimates. The quarter was a mix of "extremely strong" organic growth aided by currency tailwinds, Munda tells investors in a post-earnings research note. He believes the company's updated guidance remains conservative and keeps a Buy rating on Altair.
06/15/18
BREN
06/15/18
NO CHANGE
Target $43
BREN
Buy
Altair price target raised to $43 from $36 at Berenberg
Berenberg analyst Gal Munda raised his price target for Altair Engineering to $43 and keeps a Buy rating on the shares. Following the recent capital raise, the company has the ability to make further acquisitions which would serve to further accelerate top-line growth, Munda tells investors in a research note. He notes that Altair is currently generating "industry-leading" revenue growth at around 12%-13% per year.
06/11/18
RBCM
06/11/18
NO CHANGE
Target $38
RBCM
Sector Perform
Altair price target raised to $38 from $33 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on Altair to $38 ahead of his meeting with the management in the coming week. The analyst points to "strong execution" and peer-group multiple expansion, keeping his Sector Perform rating on Altair.
WOW WideOpenWest
$10.93

0.1 (0.92%)

07/10/18
FBCO
07/10/18
INITIATION
Target $10.5
FBCO
Neutral
WideOpenWest initiated with a Neutral at Credit Suisse
Credit Suisse analyst Douglas Mitchelson initiated WideOpenWest with a Neutral rating and a price target of $10.50. The analyst notes that the company is competing with much larger players in an industry where "scale matters", adding that while the CEO has reset expectations after "disappointing" 2017 results, the company still needs to demonstrate some operating stability to "rebuild" investor confidence and return to growth. At current prices, Mitchelson believes that risk-reward on WideOpenWest is balanced.
06/21/18
RILY
06/21/18
INITIATION
Target $14
RILY
Buy
WideOpenWest initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Zack Silver started WideOpenWest with a Buy rating and $14 price target.
05/16/18
KEYB
05/16/18
INITIATION
KEYB
Sector Weight
WideOpenWest initiated with a Sector Weight at KeyBanc
KeyBanc analyst Brandon Nispel initiated WideOpenWest with a Sector Weight saying it operates with the most competitive overlap of all cable companies, will struggle to grow organically, and a potential deceleration in organic broadband creates uncertainty.
03/22/18
03/22/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Visteon (VC) double-downgraded to Underweight from Overweight at Morgan Stanley with analyst Armintas Sinkevicius saying the auto industry is going through an "unprecedented period of cyclical and secular change" and investors are currently skewed negative on U.S. autos and shared mobility stocks. 2. Trivago (TRVG) downgraded to Underweight from Neutral at JPMorgan with analyst Doug Anmuth saying he thinks hotel meta search will "remain challenged." 3. SiriusXM (SIRI) downgraded to Neutral from Buy at Citi with analyst Jason Bazinet saying he expects Sirius' free cash flow per share growth rate to decelerate from over 20% growth in 2018 and 2019 to low-double digit growth in 2020. 4. Delphi Technologies (DLPH) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Armintas Sinkevicius saying he believes the company could become an acquirer and has concerns with the guidance assumptions around diesel penetration. 5. WideOpenWest (WOW) downgraded to Sector Perform from Outperform at RBC Capital with analyst Jonathan Atkin saying higher investment in care and marketing this year suggest the company faces competitive challenges and slower EBITDA growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LGF Use LGF.A, LGF.B
$0.00

(0.00%)

03/21/18
LOOP
03/21/18
NO CHANGE
Target $36
LOOP
Buy
Lionsgate shares offer attractive entry at current levels, says Loop Capital
After hosting a dinner with CFO James Barge, Loop Capital analyst Alan Gould continues to believe Lionsgate Entertainment is well positioned "operating in the sweet spot" of the media industry and content creation. The company offers an "attractive asset" in a consolidating industry environment, Gould tells investors in a research note. The analyst thinks lower expectations have created an attractive entry price. He keeps a Buy rating on Lionsgate with a $36 price target.
05/17/18
KEYB
05/17/18
NO CHANGE
KEYB
Sector Weight
Lionsgate risk/reward 'slightly positive' after selloff, says KeyBanc
KeyBanc analyst Evan Wingren sees a "slightly positive" risk/reward on Lionsgate following the recent pullback, which the analyst attributes to lower growth rates and likely continued pressure on Starz subs and profits. The analyst, however, keeps a Sector Weight rating on the name. He says confidence in the company's growth reacceleration or M&A potential would likely get him more constructive.
07/19/18
RHCO
07/19/18
UPGRADE
Target $27
RHCO
Buy
Lionsgate upgraded to Buy at SunTrust on stronger Starz slate
As reported earlier, SunTrust analyst Matthew Thornton upgraded Lionsgate (LGF.B) to Buy from Hold, citing expectations of a stronger content slate at Starz driving the higher subscriber count while also increasing its distribution, with the addition of Amazon (AMZN) UK/Germany, YouTube (GOOGL) TV USA, Hulu TV USA, and Bell Canada. The analyst also anticipates higher subs count amid abating Starz MVPD headwinds from international expansion and secular growth in OTT. Thornton lowers his price target to $27 from $31, but notes that his target multiple assumption and OIBDA forecast for FY19 and FY20 are largely unchanged.
07/19/18
IMPC
07/19/18
INITIATION
Target $28
IMPC
Outperform
Lionsgate initiated with an Outperform at Imperial Capital
Imperial Capital analyst David Miller started Lionsgate (LGF.B) with an Outperform rating and $28 price target. Lionsgate is one of the "cleanest names" in the Media/Entertainment space, and perhaps the cleanest of any name in the small-to-mid cap Media sub-space, Miller tells investors in a research note. He believes the company's overall strategy and niche in the marketplace is "simple to digest and investor friendly."
PLNT Planet Fitness
$48.88

0.55 (1.14%)

07/23/18
DADA
07/23/18
NO CHANGE
Target $56
DADA
Buy
Planet Fitness price target raised to $56 from $45 at DA Davidson
DA Davidson analyst Michael Kawamoto raised his price target on Planet Fitness to $56 and kept his Buy rating, citing the company's position as the "leading franchised gym concept" poised for further growth in overall revenues and same store sales. The analyst also points to its plans for new equipment options which will provide a "more personalized and connected experience for Planet Fitness members", noting that its current testing of multiple equipment manufacturers after the recent expiration of Life Fitness contract will allow it to differentiate the members' gym experience from the competition.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $51
PIPR
Overweight
Planet Fitness price target raised to $51 from $47 at Piper Jaffray
Piper Jaffray analyst Peter Keith raised his price target for Planet Fitness to $51 following the company's announced debt refinance. Importantly, Planet Fitness will likely use an increased cash position to begin repurchasing stock as early as Q4, Keith tells investors in a research note. The analyst finds it reasonable that the company can repurchase $400M-$900M of stock in 2019, or 10%-20% of its market capitalization. He reiterates an Overweight rating on the shares.
06/25/18
BARD
06/25/18
NO CHANGE
Target $50
BARD
Outperform
Planet Fitness price target raised to $50 from $45 at Baird
Baird analyst Jonathan Komp raised his price target on Planet Fitness to $50 from $45 based on its bullish long-term outlook on a sizable opportunity, multiple comp drivers, attractive financial model, and addition upside levers. Komp reiterated his Outperform rating on Planet Fitness shares.
06/20/18
BREN
06/20/18
INITIATION
Target $53
BREN
Buy
Planet Fitness initiated with a Buy at Berenberg
Berenberg started Planet Fitness with a Buy rating and $53 price target.
AL Air Lease
$44.15

-0.21 (-0.47%)

03/09/18
BOFA
03/09/18
UPGRADE
Target $56
BOFA
Buy
Air Lease upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Kristine Liwag upgraded Air Lease to Buy from Neutral and maintained a $56 price target saying the recent pullback in shares provides an attractive entry point. Liwag is also positive on Air Lease's high earnings visibility, experienced management team, strong balance sheet, and said there is limited risk from steel/aluminum tariffs and rising rates.
03/13/18
MACQ
03/13/18
INITIATION
Target $53
MACQ
Outperform
Air Lease initiated with an Outperform at Macquarie
Macquarie initiated Air Lease with an Outperform and $53 price target.
03/14/18
MACQ
03/14/18
INITIATION
Target $53
MACQ
Outperform
Air Lease initiated with an Outperform on solid growth at Macquarie
Macquarie analyst Susan Donofrio initiated Air Lease with an Outperform and $53 price target. Donofrio said the company is positioned for stable earnings and strong profitability driven by a young fleet, solid growth profile and experienced management team.
07/31/18
07/31/18
DOWNGRADE
Target $64

Equal Weight
AerCap downgraded to Equal Weight after outperformance at Stephens
As previously reported, Stephens analyst Vincent Caintic downgraded AerCap (AER) to Equal Weight from Overweight, noting that the stock has outperformed both Air Lease (AL) and Aircastle (AYR) year-to-date. Caintic is finding it more difficult for AerCap to show core EPS growth without "lofty assumptions" and prefers Aer Lease, which he thinks can continue with double-digit EPS growth year-over-year. He maintains a $64 price target on AerCap shares.
SYNA Synaptics
$48.15

-0.995 (-2.02%)

08/01/18
CHLM
08/01/18
UPGRADE
CHLM
Buy
Synaptics upgraded to Buy from Hold at Craig-Hallum
08/01/18
KEYB
08/01/18
NO CHANGE
KEYB
Apple's results positive for supply-chain companies, says KeyBanc
KeyBanc analyst John Vinh views Apple's (AAPL) "solid" results as positive for the company's supply-chain companies Broadcom (AVGO), Cirrus Logic (CRUS), Qorvo (QRVO), Skyworks (SWKS), and Synaptics (SYNA), as results indicate that demand has finally stabilized ahead of the new iPhone ramp. Additionally, lean channel commentary gets him incrementally more positive ahead of the new iPhone ramp, he contends. Vinh's favorite Apple supply-chain names are Broadcom, Qorvo, Skyworks, and Synaptics.
06/21/18
06/21/18
DOWNGRADE
Target $51

Hold
Synaptics downgraded to Hold on buyout concerns at Craig-Hallum
As previously reported, Craig-Hallum analyst Anthony Stoss downgraded Synaptics (SYNA) to Hold from Buy, with an unchanged price target of $51, as he believes it is unlikely that the company would accept a buyout price that Dialog Semiconductor (DLGNF) could comfortably afford, and the stock could likely be under pressure if and when the potential deal falls through.
08/01/18
08/01/18
UPGRADE
Target $51

Buy
Synaptics upgraded to Buy after deal talks end at Craig-Hallum
As previously reported, Craig-Hallum analyst Anthony Stoss upgraded Synaptics (SYNA) to Buy from Hold, with a $51 price target, after the company confirmed that it has terminated buyout discussions with Dialog Semiconductor (DLGNF). The analyst notes that he never believed the Dialog Semiconductor deal would happen, and thinks the risk reward tilts back in favor of owning shares.
OSTK Overstock.com
$38.60

1.55 (4.18%)

04/03/18
PIPR
04/03/18
NO CHANGE
Target $92
PIPR
Overweight
Wayfair valuation becoming attractive, says Piper Jaffray
Piper Jaffray analyst Peter Keith lowered his price target for Wayfair to $92 from $112 but says the valuation is becoming attractive following the recent selloff. The analyst reiterates an Overweight rating on the shares. The pending Supreme Court case on e-commerce sales tax should be a relative non-event for Wayfair, Keith tells investors in a research note. Further, the analyst believes recent comments by Overstock.com (OSTK) to gain share through increased spending "appears likely easier said than done." Keith thinks Way-day - Wayfair's Prime-day equivalent - will run during Q2 and likely serve as a near-term positive.
04/03/18
DADA
04/03/18
NO CHANGE
Target $100
DADA
Buy
Overstock's e-commerce and Medici Ventures still offer value, says DA Davidson
DA Davidson analyst Tom Forte keeps his Buy rating and $100 price target on Overstock.com, saying the company's legacy e-commerce business and its cryptocurrency exposure through the Medici Ventures subsidiary offer "significant value". Forte believes the e-commerce business alone could be valued at $48 per share on speculation of a strategic tie-up as he anticipates a "material improvement" in sales trends in Q1. The analyst also sees the completion of the tZERO ICO as a significant potential near-term catalyst.
05/03/18
DADA
05/03/18
NO CHANGE
Target $60
DADA
Underperform
Wayfair price target raised to $60 from $55 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Wayfair (W) to $60 after its Q1 results, saying the company outperformed on sales and EBITDA while its outlook for FY18 was also better than initially projected. The analyst keeps his Underperform rating however, noting continued competitive pressure from Overstock (OSTK) and attributing the stronger Q1 in part to Way Day discounting / pulled demand.
07/02/18
DADA
07/02/18
NO CHANGE
Target $103
DADA
Buy
Overstock.com price target raised to $103 from $100 at DA Davidson
DA Davidson analyst Tom Forte raised his price target on Overstock.com to $103 and kept his Buy rating, saying that Friday marked a catalyst for the company after the management indicated that it was on track to raise $328M from its tZero ICO. Forte states that figure was above the $250M low end of the projected range. The analyst is also positive on other catalysts for Overstock.com, such as the potential sale of a minority interest in tZERO, improving trends for its legacy e-commerce business, and an eventual sale of its legacy home e-commerce business to a strategic buyer.
TSLA Tesla
$352.08

-18.12 (-4.89%)

08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.
08/08/18
08/08/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. REACTIONS TO TESLA'S TALK OF GOING PRIVATE: Jefferies analyst Philippe Houchois raised his price target for Tesla (TSLA) to $360 from $250 after CEO Elon Musk suggested taking the company private. Going private "feels like the right thing to do," Houchois said. "Distraction or not, the move feels right even if Musk is downplaying how supportive public markets have been," the analyst adds. However, with Tesla unable to take on more debt, Houchois wondered who may fund the potential deal and end up as a new large shareholder. While Morgan Stanley analyst Adam Jonas sympathizes with Elon Musk's argument that Tesla could be better off as a private company, he questioned the feasibility of Musk actually being able to achieve that goal. Taking the company private would assume either that the company is on the verge of generating self-sustaining cash flows or that it can tap into a range of strategic sources of capital not previously at its disposal, said Jonas, who sees strategic value at Tesla but thinks the "LBO math required to support [a price of] $420 is extremely aggressive." MORGAN STANLEY SAYS SOUTHWEST A GOOD FIT FOR BERKSHIRE: Morgan Stanley analyst Kai Pan noted that Berkshire Hathaway (BRK.A) has shifted tone in recent years and become a top three shareholder of the "Big Four" U.S. airlines, including Southwest (LUV). Media reports from Forbes, CNN and others have discussed a possible acquisition by Berkshire of the airline, added Pan. He analyzed a theoretical acquisition and came to the conclusion that Southwest could be a strategic fit for Berkshire and the advantages could also be compelling for the airline. Pan estimates Berkshire could pay a 20-40% premium, or $70-80 per share for Southwest, in such a hypothetical takeover situation. Pan has an Overweight rating and $67 price target on Southwest shares. BARCLAYS POSITIVE ON SNAP GUIDANCE CHANGE: Barclays analyst Ross Sandler views Snap's (SNAP) Q2 results as a "mixed bag," with daily active users 2M below his estimate and revenue $20M above his estimate. More importantly, the change in approach towards guidance is "very welcomed and should help to reduce some of the volatility going forward," Sandler said. He believes this is a "big positive for long-term holders looking to get involved." The analyst kept an Overweight rating on Snap with a $16 price target. WAINWRIGHT SAYS INSMED LIKELY TO BE ACQUIRED: H.C. Wainwright analyst Andrew Fein raised his price target for Insmed (INSM) to $43 from $35 following the 12-2 FDA panel vote in favor of ALIS in refractory nontuberculous mycobacterial patients. Insmed is now likely to be acquired as ALIS "fits well within the pipeline of a number of larger companies," Fein said.
08/08/18
BARD
08/08/18
NO CHANGE
Target $411
BARD
Outperform
Tesla $420 buyout price mentioned by Musk too low, says Baird
Baird analyst Ben Kallo believes the Tesla buyout price of $420 mentioned by Elon Musk is too low. He expects the shares to trade above that mark as investors will demand a higher premium, which will coincide with short covering. Kallo reiterated his Outperform rating and $411 price target on Tesla shares.
08/08/18
MSCO
08/08/18
NO CHANGE
Target $291
MSCO
Equal Weight
Musk may want to take Tesla private, but Morgan Stanley questions feasibility
While Morgan Stanley analyst Adam Jonas sympathizes with Elon Musk's argument that Tesla could be better off as a private company, he questions the feasibility of Musk actually being able to achieve that goal. Taking the company private would assume either that the company is on the verge of generating self-sustaining cash flows or that it can tap into a range of strategic sources of capital not previously at its disposal, said Jonas, who sees strategic value at Tesla but thinks the "LBO math required to support [a price of] $420 is extremely aggressive." The benefits of being private are outweighed by the risks of added financial leverage, which could be even more strategically limiting, added Jonas, who keeps an Equal Weight rating on Tesla shares with a price target of $291.
CORT Corcept Therapeutics
$14.00

-0.08 (-0.57%)

05/31/18
05/31/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Paccar (PCAR) downgraded to Neutral from Buy at Goldman Sachs with analyst Jerry Revich saying that while U.S. truck spot market indicators have stabilized at new cycle highs amid robust freight demand and a tight trucking labor market, the load-truck ratio - a leading indicator - has declined about 30% over the past 4 months. 2. MAA (MAA) downgraded to Neutral from Buy at BTIG with analyst James Sullivan saying he expects lower relative valuations for Apartment REITs following the "mediocre" quarterly results. 3. Micron (MU) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Joseph Moore saying he believes the continued strength in DRAM looks priced in and the NAND recovery that bulls are looking for in the second half of the year looks "increasingly unlikely." 4. Corcept Therapeutics (CORT) downgraded to Hold from Buy at Stifel with analyst Adam Walsh saying results are due near-term for both Strongbridge Biopharma's (SBBP) Recorlev and Novartis' (NVS) osilodrostat. 5. DSW (DSW) downgraded to Neutral from Positive at Susquehanna with analyst Sam Poser citing limited valuation upside. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/18
05/31/18
DOWNGRADE
Target $20

Hold
Corcept Therapeutics downgraded to Hold ahead of competitive read outs at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded Corcept Therapeutics (CORT) to Hold from Buy, noting that results are due near-term for both Strongbridge Biopharma's (SBBP) Recorlev and Novartis' (NVS) osilodrostat. While he does not have a clear read on the potential for positive outcomes for these candidates, Walsh thinks the impending read outs could create an overhang for Corcept shares, he tells investors. The analyst, who also notes a lack of FDA clarity on the Phase 3 trial design for Corcept's second-gen Cushing's candidate relacorilant, keeps a $20 price target on Corcept shares.
05/31/18
STFL
05/31/18
DOWNGRADE
STFL
Hold
Corcept Therapeutics downgraded to Hold from Buy at Stifel
04/13/18
GHSC
04/13/18
INITIATION
Target $32
GHSC
Buy
Corcept Therapeutics initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Corcept Therapeutics with a Buy and $32 price target citing long-term organic growth, Korlym remains underpenetrated in Cushing's syndrome, low consensus estimates, and upcoming relacorilant final Phase 2 data in Q3 that could act as a major catalyst.
RUN Sunrun
$14.33

0.03 (0.21%)

08/03/18
MSCO
08/03/18
DOWNGRADE
MSCO
Equal Weight
Sunrun downgraded to Equal Weight from Overweight at Morgan Stanley
08/03/18
08/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Luna Innovations (LUNA) downgraded to Market Perform from Outperform at Northland with analyst Tim Savageaux saying he sees the shares reflecting the value of the "well executed" sale of the Opto Solutions unit at current levels. 2. State Street (STT) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Brian Kleinhanzl warning that the deal has increased the risks for State Street investors, while the anticipated revenue synergies may not emerge. 3. Sunrun (RUN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Stephen Byrd saying he thinks the stock now prices in favorable industry developments and a longer growth runway following its 60% appreciation since the start of April and 150% year-to-date advance. 4. Motorola Solutions (MSI) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster saying he views the company's Q2 results as solid but feels the guidance is mixed. 5. Gildan Activewear (GIL) downgraded to Hold from Buy at Desjardins. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/18
GSCO
07/18/18
DOWNGRADE
Target $15
GSCO
Neutral
Sunrun downgraded to Neutral at Goldman Sachs on valuation
As reported earlier, Goldman Sachs analyst Brian Lee downgraded Sunrun to Neutral from Buy as part of his broader research note on the solar sector and also kept his price target at $15 citing valuation on the stock. The analyst states that Sunrun has already run up 160% year to date and also cites the shift in China's solar policy in late May along with the ensuing price collapse across the supply chain toward quarter-end, which raises the risk of margin misses and weaker Q3 guidance. Lee adds that China-levered names like Jinko Solar (JKS) and Canadian Solar (CSIQ) thus face particularly challenging demand outlooks. The analyst has the most constructive view on the U.S. residential installer Vivint Solar (VSLR), which stands to "benefit from lower module costs and what we expect could close the valuation gap relative to peers.
08/03/18
08/03/18
DOWNGRADE
Target $15

Equal Weight
Sunrun downgraded to Equal Weight after 150% year-to-date run at Morgan Stanley
As previously reported, Morgan Stanley analyst Stephen Byrd downgraded Sunrun to Equal Weight from Overweight, as he thinks the stock now prices in favorable industry developments and a longer growth runway following its 60% appreciation since the start of April and 150% year-to-date advance. The analyst, who sees competitive pressure and rising interest rates as key risks, raised his price target on Sunrun shares to $15 from $8.
AVLR Avalara
$46.05

3.55 (8.35%)

07/10/18
JMPS
07/10/18
INITIATION
JMPS
Market Perform
Avalara initiated with a Market Perform at JMP Securities
JMP Securities analyst Patrick Walravens started Avalara with a Market Perform rating, stating that the story includes a number of positive elements, but also noting that the stock is up 98% from its IPO price due to investor optimism about the U.S. Supreme Court decision on online sales tax collection. Given the run-up since the court decision, Walravens sees Avalara shares as fairly valued, he tells investors in his initiation note.
07/10/18
KEYB
07/10/18
INITIATION
KEYB
Sector Weight
Avalara initiated with a Sector Weight at KeyBanc
KeyBanc analyst Brent Bracelin started Avalara with a Sector Weight rating on valuation given investor optimism has been reflected in a share price that has risen 98% since the IPO. Nonetheless, the analyst has a bullish medium- to long-term view on Avalara based on its leadership in cloud software for sales tax compliance, differentiated tax content and software integrations, large $8B addressable market with less than 2% penetration, and long runway to sustain 20%-plus annual growth for the next decade.
07/16/18
JMPS
07/16/18
NO CHANGE
JMPS
Market Perform
Etsy comments hint at possible competitive moat for Avalara, says JMP Securities
After reviewing the South Dakota v. Wayfair Supreme Court opinion and some of the related Amicus Curiae briefs, JMP Securities analyst Patrick Walravens highlighted a comment from Etsy's (ETSY) brief that concluded that "given this complexity [of mapping thousands of tax codes to millions of unique products], it is doubtful that a software fix ever can be developed." Rather than doubting that a software solution can ever be developed, Walravens said he views the complexity referenced by Etsy as the market opportunity and potential competitive moat for Avalara, he tells investors. Still, Walravens believes Avalara is currently fairly valued and maintains his Market Perform rating on the shares.
07/10/18
STFL
07/10/18
INITIATION
Target $44
STFL
Hold
Avalara initiated with a Hold at Stifel
Stifel analyst Brad Reback initiated Avalara with a Hold rating and $44 price target, stating that he believes the company has a large and underpenetrated market opportunity and unique go-to-market approach, but he also believes all of this is fully reflected in the current share price.
RDFN Redfin
$23.12

0.44 (1.94%)

06/25/18
ZELM
06/25/18
INITIATION
ZELM
Buy
Redfin initiated with a Buy at Zelman
06/18/18
06/18/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Redfin (RDFN) was downgraded to Sell from Neutral at Goldman Sachs while Zillow (Z, ZG) was downgraded to Neutral from Buy. 2. Dun & Bradstreet (DNB) downgraded to Neutral from Outperform at Baird with analyst Jeffrey Meuler saying he believes any potential take-out is already priced into the shares, the current valuation seems to limit potential upside, and the business requires more substantial changes to return it to sustainable organic growth. 3. Hibbett Sports (HIBB) downgraded to Underperform from Buy at BofA/Merrill analyst Rafe Jadrosich saying he expects negative same-store-sales declines in Q4 and continuing through 2020 as Hibbett laps the ecommerce launch and excess inventory clearance. 4. Cheesecake Factory (CAKE) downgraded to Neutral on valuation at BTIG with analyst Peter Saleh citing recent share strength. 5. Intel (INTC) downgraded to Underperform from Market Perform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/18
GSCO
06/18/18
DOWNGRADE
Target $21
GSCO
Sell
Redfin downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Heath Terry downgraded Redfin (RDFN) to Sell with an unchanged price target of $21. Macro pressures have an outsized impact on Redfin, Terry tells investors in a research note. He downgraded the online real estate stocks ahead of what has historically been a period of seasonal underperformance, along with expectations for continued tightness in housing and mortgage availability as well as signs of increasing competition in the online real estate category. Terry this morning also downgraded Zillow Group (ZG) to Neutral.
05/22/18
DADA
05/22/18
NO CHANGE
Target $28
DADA
Buy
Redfin listing market share gains are accelerating, says DA Davidson
DA Davidson analyst Tom White kept his Buy rating and $28 price target on Redfin, saying his tracking of for-sale residential home listings across 26 markets over the past 10.5 weeks suggests that the company's pace of market share gains is accelerating. Given the current 1.4K listings in 26 markets - about 0.7% of all listed homes in the area - White calculates that Redfin's listing share has increased by 0.005% per day since May 2nd, which is up from 0.04% acceleration in the prior 10 weeks. The analyst believes that Redfin's market share gains will likely remain impressive, though the low for-sale inventory could keep the pressure on the company's revenue and EBITDA upside.
DBX Dropbox
$34.40

2.86 (9.07%)

05/11/18
ADAM
05/11/18
NO CHANGE
Target $36
ADAM
Buy
Dropbox weakness a buying opportunity, says Canaccord
Canaccord analyst Richard Davis noted Dropbox shares sold off following its Q1 earnings release but he said he would be an "aggressive buyer" of the shares using the weakness as a buying opportunity. He noted the company delivered upside on every metric and made progress on customer additions, ARPU, and product innovation. Davis reiterated his Buy rating and raised his price target to $36 from $35 on Dropbox shares.
05/17/18
DBAB
05/17/18
NO CHANGE
DBAB
Buy
Google changes unlikely to impact Dropbox, says Deutsche Bank
Dropbox (DBX) rival Google (GOOG, GOOGL) this week announced some changes to its consumer-based cloud storage service, Deutsche Bank analyst Karl Keirstead tells investors in a research note. The analyst notes that Google is moving all paid Google Drive consumer subscribers to a newly named Google One service, which includes added storage capacity options, "expert assistance" and the ability to add family members. Google also cut the price of its 2TB capacity plan in half, to $10 from $20 per month, Keirstead adds. He does not see these changes materially impacting Dropbox and keeps a Buy rating on the shares.
08/01/18
JEFF
08/01/18
UPGRADE
Target $32
JEFF
Buy
Dropbox upgraded to Buy from Hold at Jefferies
Jefferies analyst John DiFucci upgraded Dropbox to Buy with an unchanged price target of $32. The analyst is not making a call on the Q2 results, which come on August 9. Rather, the upgrade is based "entirely on valuation." The stock is down 16% over the past week "on no material change," DiFucci tells investors in a research note. He continues to view Dropbox's "attractive, sustainable model as unique in software."
08/01/18
08/01/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JEFFERIES UPGRADES DROPBOX TO BUY: Jefferies analyst John DiFucci upgraded Dropbox (DBX) to Buy from Hold with an unchanged price target of $32. The analyst is not making a call on the Q2 results, which come on August 9. Rather, the upgrade is based "entirely on valuation," he stated. Dropbox is up 4.7% in late morning trading. JEFFERIES UPGRADES PAPA JOHN'S: Jefferies analyst Alexander Slagle upgraded Papa John's (PZZA) to Buy from Hold and raised his price target for the shares to $58 from $52. The stock, down 50% from highs, now reflects the likelihood that fundamentals will get worse before improving, Slagle said. After reviewing the company's potential path to recovery and possible strategic actions that could create shareholder value, the analyst has a bull case of $75 per share. He thinks this outweighs the bear case, or downside risk, of $35 per share. SAREPTA UPGRADED AFTER PULLBACK: Morgan Stanley analyst Matthew Harrison upgraded Sarepta Therapeutics (SRPT) to Overweight from Equal Weight, noting that the stock has given up much of the gains it saw when its initial DMD gene therapy data was announced. He sees the pullback as an opportunity to own the stock near pre-DMD gene therapy levels without taking the binary risk. He doesn't think a major bear case has emerged on the prospects for the company's DMD gene therapy program and he sees major catalysts in the second half of this year that he believes the market is missing. Harrison has a $163 price target on Sarepta shares. PIPER CUTS SHOPIFY TO NEUTRAL: Piper Jaffray analyst Michael Olson downgraded Shopify (SHOP) to Neutral from Overweight and lowered his price target to $145 from $155, saying that Shopify's Q2 was "good, but not good enough" with monthly recurring revenue below investor expectations. While Olson said Shopify is performing well, he believes their performance is mostly reflected in the stock's current valuation. PIPER RECOMMENDS BIOGEN AFTER MANAGEMENT MEETING: After hosting investor meetings with Biogen (BIIB) investor relations this week, Piper Jaffray analyst Christopher Raymond came away feeling like the "all-important" high-dose APOE4 subset analysis of the BAN2401 results "may be provided sooner than later." If shown to have little impact on the overall placebo-adjusted ADCOMS benefit, this should be an important event, Raymond said. Coupling this with "continued solid commercial momentum and a host of other value-enhancing catalysts," the analyst continues to like the risk/reward on Biogen. He kept an Overweight rating on shares with a $400 price target.
MCHP Microchip
$98.07

0.3 (0.31%)

08/09/18
MSCO
08/09/18
NO CHANGE
MSCO
Morgan Stanley downgrades semiconductor industry view to Cautious
Morgan Stanley analyst Joseph Moore said he has become less constructive on semiconductor stocks through the year and he now believes elevated inventory levels and stretched lead times leave "no margin for error." Given his view that any lead time adjustment or demand slowdown could drive a "meaningful correction," Moore has downgraded his semiconductor industry view to Cautious from In-Line. He favors connector companies, like Amphenol (APH) and TE Connectivity (TEL) over analog/MCU at this point in the cycle, due to lower risk around lead time issues, Moore said. He also has a "strong preference" for high margin and more defensive models, such as Analog Devices (ADI) over lower margin and commodity exposed ones, like Cypress Semiconductor (CY) and ON Semiconductor (ON), he said. Despite his more cautious view on the space, Moore keeps Overweight ratings on Nvidia (NVDA), Xilinx (XLNX) and Ambarella (AMBA), citing his view that they should benefit from secular growth in the area of AI, data center, and autonomous. Other semiconductor names include Microchip (MCHP), Qorvo (QRVO), Micron (MU), Intel (INTC), Broadcom (AVGO) and Qualcomm (QCOM).
07/23/18
MSCO
07/23/18
NO CHANGE
MSCO
Tariff uncertainty a potential risk to semiconductor demand, says Morgan Stanley
Morgan Stanley analyst Joseph Moore said the firm's quarterly survey of distributors leads him to expect "solid" Q2 results and Q3 guidance from broad-based semiconductor companies this earnings season as demand remains strong. However, the present tariff related uncertainty present a risk for a "demand shock" that could lead to an inventory unwind in the semi supply chain, Moore warns investors. He thinks the potential of further semi stock outperformance is limited at this stage of the cycle, while "even the slightest whiff on the demand front" could lead to a significant decline in stocks, he tells investors. Moore added that he favors companies with more defensive characteristics, such as Analog Devices (ADI), over those with more commodity exposure and lower margins, like Cypress Semiconductor (CY). Other publicly traded companies in the semiconductors space include Micron (MU), AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Nvidia (NVDA), Qualcomm (QCOM) and Texas Instruments (TXN). Shares of Micron are down 2.5% in pre-market trading to $53.65.
07/27/18
PIPR
07/27/18
NO CHANGE
Target $150
PIPR
Overweight
Microchip price target raised to $150 from $110 at Piper Jaffray
Piper Jaffray analyst Harsh Kumar raised his price target for Microchip Technology to $150 ahead of the company's Q2 results. The analyst believes Microchip has "significant room" to continue to beat earnings estimates for several quarters in a row. Further, his sensitivity analysis shows the company has the ability to generate "significant" free cash flow in order to meet both the dividend and the debt obligations, even if the company growth were to slow down to 0% or even potentially decline by 3%. He keeps an Overweight rating on Microchip shares.
07/19/18
NOMU
07/19/18
INITIATION
NOMU
Nomura rolls out Analog Semi coverage, names ON top pick
Nomura Instinet analyst Krysten Sciacca last night rolled out coverage on Analog Semiconductors. The analyst expects the group to outperform throughout the remainder of 2018 given its "steadier business models" versus other semi sectors, "strong" free cash flow generation and the "strong" demand coming from the auto and industrial applications. Her top pick is ON Semiconductor (ON), which the analyst initiated with a Buy rating and $30 price target. ON currently trades at a 35% discount to the Analog group, but its multiple should expand as investors come to better appreciate the company's exposure to industrial and auto, Sciacca told investors in a research note. She believes the company's 2020 target model will likely prove conservative. Sciacca also initiated coverage of Microchip (MCHP) with a Buy rating and $110 price target. The stock currently trades at a 22% discount to the comp group, but its "aggressive" de-leveraging, market share gains, and "strong" executional track record warrant the stock returning to its historical five-year average premium of 2%, the analyst contends. She initiated Cree (CREE) with a Hold rating and $44 price target saying the stock is already pricing in tailwinds and assumed coverage of Analog Devices (ADI) with a Neutral rating and $100 price target.
JCOM j2 Global
$86.34

0.735 (0.86%)

02/02/18
DADA
02/02/18
INITIATION
Target $95
DADA
Buy
j2 Global initiated with a Buy at DA Davidson
DA Davidson analyst Rishi Jaluria initiated j2 Global with a Buy rating and a price target of $95, saying the company acquisition strategy is akin to private equity in "buying underperforming assets in cloud services and digital media and achieving scale through a roll-up strategy". The analyst is also positive on j2 Global's operating margin expansion and potential for further gains along with its attractive valuation relative to the peer group.
05/09/18
DADA
05/09/18
NO CHANGE
Target $100
DADA
Buy
j2 Global price target raised to $100 from $95 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on J2 Global to $100 after its Q1 earnings, saying the results were driven by a 16% revenue increase in digital media. The analyst notes that the segment is increasingly more focused on subscription revenue, which has grown to 22% of digital media's total sales from 12% last quarter, adding that EBITDA margins are also expected to improve after some compression in Q1. Jaluria keeps his Buy rating on J2 Global.
CHUY Chuy's
$30.90

0.25 (0.82%)

08/30/17
08/30/17
NO CHANGE

Wedbush estimates Harvey's impact on restaurant chains
Wedbush analyst Nick Setyan says that Jack in the Box (JACK), Fiesta Restaurant (FRGI), Chuy's (CHUY), Cheesecake Factory (CAKE), and BJ's Restaurants (BJRI0 have the most exposure to Hurricane Harvey among restaurant owners. The analyst estimates that 20% of restaurants owned by Jack in the Box are in the area and 27% of Fiesta's Taco Cabana restaurants are in Houston, while 9% of Chuy's restaurants, 3% of Cheesecake's units, and 2% of BJ's units are in the area,. The analyst estimates that Jack in the Box's EPS loss could be as high as .007c per day, while Fiesta's EPS loss may be as high as .005c per day, and Chuy could lose .004c of EPS per day. Finally, Cheesecake and BJ's could lose u[p to .002c of EPS per day, the analyst stated.
10/02/17
STFL
10/02/17
INITIATION
STFL
Hold
Chuy's resumed coverage with a Hold at Stifel
Stifel analyst Chris O'Cull resumed coverage of Chuy's with a Hold rating and $23 price target.
01/10/18
BMOC
01/10/18
NO CHANGE
Target $30
BMOC
Market Perform
Chuy's price target raised to $30 from $24 at BMO Capital
BMO Capital analyst Andrew Strelzik raised his price target on Chuy's to $30 after hosting a meeting with the company at ICR, saying the commentary from the management gives him confidence in solid Q4 SSS trends. Strelzik keeps his Market Perform rating however, adding that risk/reward in the stock price appears to be balanced at current levels, while the outlook for margin improvement in the near term remains uncertain.
07/17/18
RAJA
07/17/18
DOWNGRADE
RAJA
Market Perform
Chuy's downgraded to Market Perform on valuation at Raymond James
Raymond James analyst Brian Vaccaro downgraded Chuy's to Market Perform from Outperform citing valuation.
MIME Mimecast
$40.23

1.84 (4.79%)

06/20/18
GSCO
06/20/18
UPGRADE
Target $53
GSCO
Buy
Mimecast upgraded to Buy with $53 price target at Goldman Sachs
Goldman Sachs analyst Gabriela Borges upgraded Mimecast to Buy from Neutral and raised her price target for the shares to $53 from $38. The company's share gain is accelerating on the back of an inflection in average order value, indicating momentum with moving up market, Borges tells investors in a research note. She believes the company "still has a good runway for share gain," and sees the potential for an expanding total addressable market as management executes on its medium-term roadmap. Further, she notes that Mimecast's free cash flow is inflecting higher and that relative to peers, the company's valuation has actually become more attractive.
05/15/18
NEED
05/15/18
NO CHANGE
Target $49
NEED
Buy
Mimecast price target raised to $49 from $46 at Needham
Needham analyst Alex Henderson raised his price target on Mimecast (MIME) to $49 and kept his Buy rating after its "strong" Q4 results and initial FY19 guidance. The analyst notes that the wider than expected loss was in part due to the costs around the company's move to Lexington headquarters. Henderson adds that the upcoming quarter will be the first under the ASC 606 model, which should weigh on revenues but also add "solidly" to operating margins. The analyst is also positive on Mimecast's expansion in Europe following a "smooth" build-out in Germany, while its partnership with Microsoft (MSFT) is not changing despite the comments made regarding security around Office 365.
05/15/18
BMOC
05/15/18
NO CHANGE
Target $48
BMOC
Outperform
Mimecast price target raised to $48 from $38 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Mimecast to $48 after the company posted another revenue beat in Q4. The analyst adds that the quarter's metrics were "solid across the board", with strong "Office 365 adoption, average order value, number of services, and new customer additions" of 1.2K vs. 1.1K in Q3. Bachman further states that the rate of customers subscribing to more than 4 services has trended up to 33% of total in Q4 vs. 29% a year ago. The analyst keeps his Outperform rating on Mimecast.
06/20/18
GSCO
06/20/18
UPGRADE
Target $53
GSCO
Buy
Mimecast upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Gabriela Borges upgraded Mimecast to Buy and raised her price target for the shares to $53 from $38. The analyst sees the company's free cash flow inflecting amid improved unit economics.
ELGX Endologix
$4.72

0.02 (0.43%)

10/09/17
ADAM
10/09/17
NO CHANGE
Target $5
ADAM
Hold
Endologix investors should take profits, says Canaccord
Canaccord analyst Jason Mills believes the run in Endologix shares following the FDA approval of the NELLIX confirmatory study is "egregiously overdone" and as a result investors should take profits. Mills, who remains cautious about the company's ability to gain market share in a highly competitive and mature market, maintained his Hold rating and $5.00 price target on Endologix shares.
12/12/17
PIPR
12/12/17
INITIATION
Target $7
PIPR
Overweight
Endologix assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brian assumed coverage of Endologix with an Overweight rating and $7 price target. The analyst views the company as a "solid player" in the abdominal aortic aneurysms space despite some setbacks.
01/02/18
JPMS
01/02/18
DOWNGRADE
Target $5
JPMS
Underweight
Endologix downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Endologix to Underweight and cut his price target for the shares to $5 from $6. The outlook for the company continued to "deteriorate" over the course of 2017 as pipeline and regulatory challenges mounted, Weinstein tells investors in a research note. He sees an "uncertain path to profitability" and a "very long" road to recovery for Endologix.
03/20/18
PIPR
03/20/18
NO CHANGE
PIPR
Endologix ENCORE study a positive sign, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien was positive on Endologix's ENCORE study results for its Ovation product, and continues to believe "additional data reads and imminent approvals in the coming years should lift shares higher." O'Brien maintained an Overweight rating on shares, recommending investors with more risk tolerance or a longer time horizon accumulate shares at this point.
ACXM Acxiom
$43.33

0.52 (1.21%)

07/17/18
WELS
07/17/18
NO CHANGE
Target $50
WELS
Outperform
Acxiom price target raised to $50 from $41 at Wells Fargo
Wells Fargo analyst William Warmington, Jr. raised his price target for Acxiom to $50 from $41 to reflect a higher multiple for LiveRamp based on a high-growth ad-tech comp set, LiveRamp's attractiveness as a strategic asset, and increased confidence in his CY2019 and CY2020 estimates. The analyst reiterates an Outperform rating on the shares.
07/03/18
WELS
07/03/18
NO CHANGE
Target $41
WELS
Outperform
Acxiom price target raised to $41 from $33 at Wells Fargo
Wells Fargo analyst William Warmington raised his price target for Acxiom (ACXM) to $41 from $33 after the company announced the sale of its Acxiom Marketing Solutions business to Interpublic Group (IPG) for $2.3B cash. The analyst reiterates an Outperform rating on Acxiom's shares.
04/16/18
BMOC
04/16/18
NO CHANGE
Target $170
BMOC
Market Perform
Facebook price target lowered to $170 at BMO Capital
BMO Capital analyst Daniel Salmon lowered his price target on Facebook (FB) to $170 from $175 and kept his Market Perform, citing the company's March 28th decision to close its Partner Categories. Salmon says that while a material revenue for Facebook from the decision is not expected, there may be some "minor" usership decline in the short run on privacy concerns and some advertisers may experience ROI degradation, just as data use platforms undergo "proactive and regulated changes". As part of his broader research note, the analyst also lowers his price target on Alliance Data Systems (ADS) to $230 from $250 and on Acxiom Corp (ACXM) to $33 from $39 with maintained Market Perform and Outperform ratings respectively.
04/04/18
SPHN
04/04/18
NO CHANGE
Target $32
SPHN
Overweight
Acxiom overreaction to Facebook news a buying opportunity, says Stephens
Stephens analyst Brett Huff noted that Acxiom (ACXM) CEO Scott Howe published a blog post stating that he has seen "some signs" that Facebook (FB) is reconsidering its new policy on data imports in light of advertiser concerns. Huff, who thinks the blog post is a potential indication of the level of concern advertisers are having about Facebook's recent move, remains a buyer of Acxiom shares as he views the recent negative stock reaction to Facebook's news as overdone. He maintains his $32 price target and Overweight rating on Acxiom shares.
FNKO Funko
$20.14

0.94 (4.90%)

07/12/18
BOFA
07/12/18
NO CHANGE
Target $17
BOFA
Buy
Funko price target raised to $17 from $13 at BofA/Merrill
BofA/Merrill analyst Rafe Jadrosich raised Buy rated Funko's price target to $17 from $13 following checks that indicate strong revenue momentum carried into Q2 and raised its 2019 earnings estimate to 88c from 84c. Jadrosich said Google search trends hit an all time high the week before Funko reached the peak search week of Comi-Con in San Dieago, Funko has more products year-to-date in the monthly top 10 toys, and its largest suppliers's revenues accelerated from 1H 2017.
07/16/18
GSCO
07/16/18
DOWNGRADE
Target $17
GSCO
Neutral
Funko downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Michael Ng downgraded Funko to Neutral while raising his price target for the shares to $17 from $14. The analyst cites valuation for the downgrade following the stock's outperformance.
07/19/18
PIPR
07/19/18
NO CHANGE
Target $18
PIPR
Overweight
Funko price target raised to $18 from $13 at Piper Jaffray
Piper Jaffray analyst Erinn Murphy raised his price target for Funko to $18 following yesterday's announcement of a Fortnite partnership hitting Holiday 2018 across 10 product styles. This follows last week's announcement of Funko and Pokemon teaming up - starting with exclusive Pop! Pikachu at Target, Murphy tells investors in a research note. Her analysis indicates these properties could lift the company's annualized base EBIT by 5%, equating to 4c in earnings per share. Murphy believes the recent license wins support Funko's "pop culture dominance." She keeps an Overweight rating on the shares.
07/24/18
JEFF
07/24/18
NO CHANGE
Target $20
JEFF
Buy
Jefferies ups Funko target to $20 after attending Comic Con
Jefferies analyst Stephanie Wissink raised her price target for Funko to $20 after attending International Comic Con in San Diego. Funko's booth "was abuzz with daily traffic," Wissink tells investors in a research note. Enthusiasm around Pokemon and Fortnite was clear at the show, the analyst adds. She upped her estimates for the second half of 2018 and keeps a Buy rating on Funko.

TODAY'S FREE FLY STORIES

VALU

Value Line

$25.00

(0.00%)

16:05
10/19/18
10/19
16:05
10/19/18
16:05
Hot Stocks
Value Line authorizes repurchase of $2M in common stock »

Value Line board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVG

Navigators

$69.31

0.1 (0.14%)

, HIG

Hartford Financial

$46.71

0.2 (0.43%)

16:05
10/19/18
10/19
16:05
10/19/18
16:05
Hot Stocks
Navigators: HSR waiting period expires for merger with Hartford subsidiary »

The Navigators Group…

NAVG

Navigators

$69.31

0.1 (0.14%)

HIG

Hartford Financial

$46.71

0.2 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GBL

GAMCO Investors

$21.03

-0.1 (-0.47%)

, TPCO

Tribune Publishing

$15.27

-0.03 (-0.20%)

16:05
10/19/18
10/19
16:05
10/19/18
16:05
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Tribune Publishing »

Gabelli reports 5.47%…

GBL

GAMCO Investors

$21.03

-0.1 (-0.47%)

TPCO

Tribune Publishing

$15.27

-0.03 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPRX

Five Prime

$14.30

0.05 (0.35%)

16:02
10/19/18
10/19
16:02
10/19/18
16:02
Hot Stocks
Breaking Hot Stocks news story on Five Prime »

Great Point Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$31.19

0.11 (0.35%)

16:02
10/19/18
10/19
16:02
10/19/18
16:02
Periodicals
GM investors not satisfied with CEO Barra's results, Reuters says »

Several General Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

BCBP

BCB Bancorp

$13.25

0.15 (1.15%)

16:01
10/19/18
10/19
16:01
10/19/18
16:01
Earnings
BCB Bancorp reports Q3 EPS 27c, consensus 28c »

Net interest margin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$153.34

-1.625 (-1.05%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:44
10/19/18
10/19
15:44
10/19/18
15:44
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) at…

IWM

iShares Trust Russell 2000 Index Fund

$153.34

-1.625 (-1.05%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$14.69

0.125 (0.86%)

15:40
10/19/18
10/19
15:40
10/19/18
15:40
Options
Call buyers in US Oil Fund as crude oil ticks higher »

Call buyers in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCHP

Microchip

$67.36

-0.18 (-0.27%)

15:35
10/19/18
10/19
15:35
10/19/18
15:35
Options
Microchip put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

15:20
10/19/18
10/19
15:20
10/19/18
15:20
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CLF

Cleveland-Cliffs

$10.92

-0.55 (-4.80%)

15:18
10/19/18
10/19
15:18
10/19/18
15:18
Hot Stocks
Breaking Hot Stocks news story on Cleveland-Cliffs »

Cleveland-Cliffs says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CLF

Cleveland-Cliffs

$10.86

-0.61 (-5.32%)

15:17
10/19/18
10/19
15:17
10/19/18
15:17
Hot Stocks
Breaking Hot Stocks news story on Cleveland-Cliffs »

Cleveland-Cliffs CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/19/18
10/19
15:17
10/19/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRX

AcelRx

$3.77

-0.38 (-9.16%)

15:16
10/19/18
10/19
15:16
10/19/18
15:16
Hot Stocks
AcelRx responds to FDA advisory committee opinions on Dsuvia »

In response to opinions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

CLF

Cleveland-Cliffs

$10.89

-0.58 (-5.06%)

15:16
10/19/18
10/19
15:16
10/19/18
15:16
Hot Stocks
Cleveland-Cliffs CEO, after berating analysts, says would handle call same way »

Cleveland-Cliffs CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/19/18
10/19
15:16
10/19/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$127.73

-6.91 (-5.13%)

, STMP

Stamps.com

$194.61

-3.18 (-1.61%)

15:08
10/19/18
10/19
15:08
10/19/18
15:08
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

SHOP

Shopify

$127.73

-6.91 (-5.13%)

STMP

Stamps.com

$194.61

-3.18 (-1.61%)

BLK

BlackRock

$402.46

2.59 (0.65%)

BX

Blackstone

$34.82

-0.45 (-1.28%)

JPM

JPMorgan

$108.18

0.05 (0.05%)

F

Ford

$8.45

-0.055 (-0.65%)

GS

Goldman Sachs

$227.49

2.55 (1.13%)

GOOGL

Alphabet Class A

$1,104.29

7.06 (0.64%)

GOOG

Alphabet

$1,095.63

7.73 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 13

    Dec

  • 26

    Feb

  • 03

    Mar

ET

Energy Transfer LP

$17.01

0.19 (1.13%)

15:04
10/19/18
10/19
15:04
10/19/18
15:04
Hot Stocks
Energy Transfer LP: Binding Expansion Open Season for Bakken Pipeline System »

Energy Transfer LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$37.87

-0.12 (-0.32%)

15:00
10/19/18
10/19
15:00
10/19/18
15:00
Options
Active trading in Halliburton ahead of earnings »

Active trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FXI

iShares China Large-Cap ETF

$39.39

0.7 (1.81%)

14:50
10/19/18
10/19
14:50
10/19/18
14:50
Options
32K iShares Large Cap China Fund Dec 42 - 44 call spreads trade for 40c »

32K iShares Large Cap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEVO

Gevo

$3.61

-0.08 (-2.17%)

, GPRE

Green Plains

$17.97

-0.38 (-2.07%)

14:48
10/19/18
10/19
14:48
10/19/18
14:48
Periodicals
Marathon weighs sale of high-ethanol gas in Minnesota, Bloomberg says »

Marathon Petroleum (MPC)…

GEVO

Gevo

$3.61

-0.08 (-2.17%)

GPRE

Green Plains

$17.97

-0.38 (-2.07%)

PEIX

Pacific Ethanol

$2.03

-0.12 (-5.58%)

MPC

Marathon Petroleum

$74.24

-4.6 (-5.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

CMCSA

Comcast

$35.94

-0.01 (-0.03%)

, CMCSK

Comcast

$0.00

(0.00%)

14:46
10/19/18
10/19
14:46
10/19/18
14:46
OnTheFly
Box Office Battle: 'Halloween' opening to add to massive October »

Comcast (CMCSA, CMCSK)…

CMCSA

Comcast

$35.94

-0.01 (-0.03%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$55.76

-0.28 (-0.50%)

T

AT&T

$32.84

0.34 (1.05%)

FOX

21st Century Fox

$45.33

-0.13 (-0.29%)

FOXA

21st Century Fox

$45.62

-0.19 (-0.41%)

DIS

Disney

$118.42

2.16 (1.86%)

LGF.A

Lionsgate

$22.17

-0.03 (-0.14%)

LGF.B

Lionsgate

$20.72

-0.06 (-0.29%)

VIA

Viacom

$36.75

-0.48 (-1.29%)

VIAB

Viacom

$33.30

-0.43 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 14

    Nov

  • 14

    Nov

FOSL

Fossil

$19.00

-0.13 (-0.68%)

14:40
10/19/18
10/19
14:40
10/19/18
14:40
Options
Far upside call buying in Fossil »

Far upside call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.67

-1.28 (-0.83%)

, GOOG

Alphabet

$1,090.00

2.1 (0.19%)

14:33
10/19/18
10/19
14:33
10/19/18
14:33
Hot Stocks
#SocialStocks: Snap may be small enough to be acquired, YouTube suffers blackout »

Welcome to…

FB

Facebook

$153.67

-1.28 (-0.83%)

GOOG

Alphabet

$1,090.00

2.1 (0.19%)

GOOGL

Alphabet Class A

$1,098.63

1.4 (0.13%)

TWTR

Twitter

$28.71

-0.58 (-1.98%)

SNAP

Snap

$6.75

-0.06 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 03

    Mar

ABBV

AbbVie

$88.84

-1.1 (-1.22%)

14:22
10/19/18
10/19
14:22
10/19/18
14:22
Recommendations
AbbVie analyst commentary  »

AbbVie's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.